Shots:
- Visirna Therapeutics, a subsidiary of Arrowhead, has granted Sanofi exclusive rights to develop & commercialize plozasiran for treating familial chylomicronemia syndrome (FCS) & severe hypertriglyceridemia (SHTG) in Greater China
- As per the deal, Visirna will receive $130M upfront & ~$265M in milestone payments across indications, along with net sales-based royalties in Greater China, as part of the Arrowhead-Visirna license partially assigned to Sanofi
- Additionally, plozasiran met its 1 & 2EPs in a P-III trial for FCS in Chinese pts, & its NDA is under NMPA review following official acceptance in Jan 2025
Ref: BusinessWire | Image: Kling Bio & Sanofi | Press Release
Related News:- Kling Bio Joins Forces with Sanofi to Identify Neutralizing Antibodies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
